Late breaking news e-poster presentation

Skeletal muscle-targeted therapies that increase contractility hold promise for the treatment of neuromuscular diseases. As a compound class, fast skeletal muscle troponin activators (FSTAs) directly increase muscle calcium (Ca ²+) sensitivity and amplify the muscle force response to subtetanic neural stimulation. Disease-modifying therapies like systemic gene transfer have previously been shown to improve muscle function in a canine model of myotubular myopathy. The purpose of the current study was to evaluate the expand ed utility of a canine skeletal muscle model to understand the pharmacokinetic/pharmacodynamic (PK/PD) relationship of the novel FSTA, CK-3762601.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research